Journal of Clinical Oncology, Vol 16, 2164-2168, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer

JD Hainsworth, HA Burris 3rd, JB Erland, M Thomas and FA Greco
Sarah Cannon-Minnie Pearl Cancer Center, Centennial Medical Center, Nashville, TN, USA.

PURPOSE: Docetaxel is a highly active antineoplastic agent; however, grade IV leukopenia occurs in the large majority of patients treated with a dose of 100 mg/m2 every 3 weeks. Recent experience with weekly paclitaxel has demonstrated a bone marrow-sparing effect when a weekly administration schedule is used. We investigated a weekly schedule of docetaxel in an attempt to alter the toxicity profile and improve the therapeutic index. PATIENTS AND METHODS: Thirty-eight patients with advanced, refractory malignancy entered this phase I trial between October 1996 and June 1997. Docetaxel was administered weekly for 6 consecutive weeks, followed by 2 weeks without treatment. Sequential cohorts of patients were treated at the following dose levels: 20, 25, 30, 36, 43, and 52 mg/m2. Patients were reevaluated after one course (8 weeks); patients with objective response or stable disease continued treatment for a maximum of four courses or until disease progression. RESULTS: Thirty-five patients completed at least one course of therapy. Myelosuppression was not a dose-limiting toxicity (DLT) at any of the doses tested. Only five episodes of grade III leukopenia occurred (14% of patients, 2% of doses), and no grade IV leukopenia was produced. No grade III or IV thrombocytopenia or anemia was observed. Grade III fatigue and asthenia were observed in all three patients treated at 52 mg/m2/wk and in two of 10 at 43 mg/m2/wk. Other grade III toxicity included acral erythema (n = 1), neuropathy (n = 1), peripheral edema (n = 1), and diarrhea (n = 1). The DLTs of this docetaxel schedule are fatigue and asthenia. Although the maximum-tolerated dose by definition of this study was 43 mg/m2/wk, we selected 36 mg/m2/wk for ongoing phase II studies. CONCLUSION: The toxicity profile of docetaxel is markedly altered when the drug is administered by a weekly schedule. Myelosuppression is mild and uncommon. Fatigue and asthenia are the DLTs; other nonhematologic toxicities, which included peripheral edema and neuropathy, are uncommon, and the arthralgia/myalgia syndrome was not observed. Weekly administration of docetaxel may provide a better tolerated, efficacious use of this drug; further investigation of weekly docetaxel as a single agent and in combination regimens is warranted.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S.-M. Tu, P. Mathew, F. C. Wong, D. Jones, M. M. Johnson, and C. J. Logothetis Phase I Study of Concurrent Weekly Docetaxel and Repeated Samarium-153 Lexidronam in Patients With Castration-Resistant Metastatic Prostate Cancer J. Clin. Oncol., July 10, 2009; 27(20): 3319 - 3324. [Abstract] [Full Text] [PDF]

				R. L. Oostendorp, A. Huitema, H. Rosing, R. S. Jansen, R. ter Heine, M. Keessen, J. H. Beijnen, and J. H.M. Schellens Coadministration of Ritonavir Strongly Enhances the Apparent Oral Bioavailability of Docetaxel in Patients with Solid Tumors Clin. Cancer Res., June 15, 2009; 15(12): 4228 - 4233. [Abstract] [Full Text] [PDF]

				S. Lorenzen, M. Hentrich, C. Haberl, V. Heinemann, T. Schuster, T. Seroneit, N. Roethling, C. Peschel, and F. Lordick Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial Ann. Onc., October 1, 2007; 18(10): 1673 - 1679. [Abstract] [Full Text] [PDF]

				J. Hong, S. H. Park, S. J. Choi, S. H. Lee, K. C. Lee, J.-I. Lee, S. Y. Kyung, C. H. An, S. P. Lee, J. W. Park, et al. Nail Toxicity after Treatment with Docetaxel: A Prospective Analysis in Patients with Advanced Non-small Cell Lung Cancer Jpn. J. Clin. Oncol., June 21, 2007; (2007) hym042v1. [Abstract] [Full Text] [PDF]

				M. Di Maio, F. Perrone, P. Chiodini, C. Gallo, C. Camps, W. Schuette, E. Quoix, C.-M. Tsai, and C. Gridelli Individual Patient Data Meta-Analysis of Docetaxel Administered Once Every 3 Weeks Compared With Once Every Week Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., April 10, 2007; 25(11): 1377 - 1382. [Abstract] [Full Text] [PDF]

				J. J. Lee, J.-Y. Han, D. H. Lee, H. Y. Kim, J. H. Chun, H. G. Lee, S. M. Yoon, S. Y. Lee, and J. S. Lee A Phase II Trial of Docetaxel Plus Capecitabine in Patients with Previously Treated Non-Small Cell Lung Cancer Jpn. J. Clin. Oncol., December 1, 2006; 36(12): 761 - 767. [Abstract] [Full Text] [PDF]

				J. P. Monk, G. Phillips, R. Waite, J. Kuhn, L. J. Schaaf, G. A. Otterson, D. Guttridge, C. Rhoades, M. Shah, T. Criswell, et al. Assessment of Tumor Necrosis Factor Alpha Blockade As an Intervention to Improve Tolerability of Dose-Intensive Chemotherapy in Cancer Patients J. Clin. Oncol., April 20, 2006; 24(12): 1852 - 1859. [Abstract] [Full Text] [PDF]

				C. Camps, B. Massuti, A. Jimenez, I. Maestu, R. G. Gomez, D. Isla, J. L. Gonzalez, D. Almenar, A. Blasco, R. Rosell, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial Ann. Onc., March 1, 2006; 17(3): 467 - 472. [Abstract] [Full Text] [PDF]

				T. C. Y. Tsao, C.-H. Chen, J. W. C. Chang, and C.-H. Lee Weekly Short Infusion of Taxotere at a 4 Week Cycle in Chinese Patients with Advanced NSCLC Who Have Failed or Relapsed after the Frontline Platinum-based Non-Taxane Chemotherapy--A Phase II Trial Jpn. J. Clin. Oncol., February 1, 2006; 36(2): 80 - 84. [Abstract] [Full Text] [PDF]

				Y. Kitamoto, T. Akimoto, H. Ishikawa, T. Nonaka, H. Katoh, T. Nakano, H. Ninomiya, K. Chikamatsu, and N. Furuya Acute Toxicity and Preliminary Clinical Outcomes of Concurrent Radiation Therapy and Weekly Docetaxel and Daily Cisplatin for Head and Neck Cancer Jpn. J. Clin. Oncol., November 1, 2005; 35(11): 639 - 644. [Abstract] [Full Text] [PDF]

				A. Eniu, F. M. Palmieri, and E. A. Perez Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast Cancer Oncologist, October 1, 2005; 10(9): 665 - 685. [Abstract] [Full Text] [PDF]

				T. Kodaira, N. Fuwa, K. Furutani, H. Tachibana, and T. Yamazaki Phase I Trial of Weekly Docetaxel and Concurrent Radiotherapy for Head and Neck Cancer in Elderly Patients or Patients with Complications Jpn. J. Clin. Oncol., April 1, 2005; 35(4): 173 - 176. [Abstract] [Full Text] [PDF]

				R. Gervais, A. Ducolone, J.-L. Breton, D. Braun, B. Lebeau, F. Vaylet, D. Debieuvre, J.-L. Pujol, J. Tredaniel, P. Clouet, et al. Phase II randomised trial comparing docetaxel given every 3 weeks with weekly schedule as second-line therapy in patients with advanced non-small-cell lung cancer (NSCLC) Ann. Onc., January 1, 2005; 16(1): 90 - 96. [Abstract] [Full Text] [PDF]

				W. K. Oh, E. Hagmann, J. Manola, D. J. George, T. D. Gilligan, J. O. Jacobson, M. R. Smith, D. S. Kaufman, and P. W. Kantoff A Phase I Study of Estramustine, Weekly Docetaxel, and Carboplatin Chemotherapy in Patients with Hormone-Refractory Prostate Cancer Clin. Cancer Res., January 1, 2005; 11(1): 284 - 289. [Abstract] [Full Text] [PDF]

				J. Tabernero, M. A. Climent, A. Lluch, J. Albanell, J. B. Vermorken, A. Barnadas, A. Anton, C. Laurent, J. I. Mayordomo, N. Estaun, et al. A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer Ann. Onc., September 1, 2004; 15(9): 1358 - 1365. [Abstract] [Full Text] [PDF]

				J. D. Hainsworth Practical Aspects of Weekly Docetaxel Administration Schedules Oncologist, September 1, 2004; 9(5): 538 - 545. [Abstract] [Full Text] [PDF]

				K.L. Tedesco, A.D. Thor, D.H. Johnson, Y. Shyr, K.A. Blum, L.J. Goldstein, W.J. Gradishar, B.P. Nicholson, D.E. Merkel, D. Murrey, et al. Docetaxel Combined With Trastuzumab Is an Active Regimen in HER-2 3+ Overexpressing and Fluorescent In Situ Hybridization-Positive Metastatic Breast Cancer: A Multi-Institutional Phase II Trial J. Clin. Oncol., March 15, 2004; 22(6): 1071 - 1077. [Abstract] [Full Text] [PDF]

				Y. Ohe, S. Niho, R. Kakinuma, K. Kubota, H. Ohmatsu, K. Goto, H. Nokihara, H. Kunitoh, N. Saijo, H. Aono, et al. A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients Ann. Onc., January 1, 2004; 15(1): 45 - 50. [Abstract] [Full Text] [PDF]

				E. Esteban, L. Gonzalez de Sande, Y. Fernandez, N. Corral, J Fra, I. Muniz, J. M. Vieitez, I. Palacio, J. L. Fernandez, E. Estrada, et al. Prospective randomised phase II study of docetaxel versus paclitaxel administered weekly in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy Ann. Onc., November 1, 2003; 14(11): 1640 - 1647. [Abstract] [Full Text] [PDF]

				J. Ballot, D. McDonnell, and J. Crown Successful Treatment of Thrombocytopenia Due to Marrow Metastases of Breast Cancer with Weekly Docetaxel J Natl Cancer Inst, June 4, 2003; 95(11): 831 - 832. [Full Text] [PDF]

				P. L. R. Mitchell, R. Basser, M. Chipman, A. Grigg, J. Cebon, I. D. Davis, J. Zalcberg, S. Ng, F. Appia, and M. Green A phase I dose-escalation study of docetaxel with granulocyte colony-stimulating factor support in patients with solid tumours Ann. Onc., May 1, 2003; 14(5): 788 - 794. [Abstract] [Full Text] [PDF]

				H. J. Stemmler, S. Kenngott, H. Diepolder, and V. Heinemann Gastrointestinal toxicity associated with weekly docetaxel treatment Ann. Onc., June 1, 2002; 13(6): 978 - 981. [Abstract] [Full Text] [PDF]

				P. Nadella, C. Shapiro, G. A. Otterson, M. Hauger, S. Erdal, E. Kraut, S. Clinton, M. Shah, M. Stanek, P. Monk, et al. Pharmacobiologically Based Scheduling of Capecitabine and Docetaxel Results in Antitumor Activity in Resistant Human Malignancies J. Clin. Oncol., June 1, 2002; 20(11): 2616 - 2623. [Abstract] [Full Text] [PDF]

				B. Esmaeli, G. Hortobagyi, F. Esteva, V. Valero, M. A. Ahmadi, D. Booser, N. Ibrahim, E. Delpassand, and R. Arbuckle Canalicular stenosis secondary to weekly docetaxel: a potentially preventable side effect Ann. Onc., February 20, 2002; 13(2): 218 - 221. [Abstract] [Full Text] [PDF]

				D. Pectasides, J. Glotsos, N. Bountouroglou, A. Kouloubinis, N. Mitakidis, N. Karvounis, N. Ziras, and A. Athanassiou Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial Ann. Onc., February 20, 2002; 13(2): 243 - 250. [Abstract] [Full Text] [PDF]

				T. Aihara, Y. Kim, and Y. Takatsuka Phase II study of weekly docetaxel in patients with metastatic breast cancer Ann. Onc., February 20, 2002; 13(2): 286 - 292. [Abstract] [Full Text] [PDF]

				G. Klement, P. Huang, B. Mayer, S. K. Green, S. Man, P. Bohlen, D. Hicklin, and R. S. Kerbel Differences in Therapeutic Indexes of Combination Metronomic Chemotherapy and an Anti-VEGFR-2 Antibody in Multidrug-resistant Human Breast Cancer Xenografts Clin. Cancer Res., January 1, 2002; 8(1): 221 - 232. [Abstract] [Full Text] [PDF]

				M. A. Ahmadi and B. Esmaeli Surgical Treatment of Canalicular Stenosis in Patients Receiving Docetaxel Weekly Arch Ophthalmol, December 1, 2001; 119(12): 1802 - 1804. [Abstract] [Full Text] [PDF]

				J. D. Hainsworth, H. A. Burris III, D. A. Yardley, J. E. Bradof, M. Grimaldi, L. A. Kalman, T. Sullivan, M. Baker, J. B. Erland, and F. A. Greco Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial J. Clin. Oncol., August 1, 2001; 19(15): 3500 - 3505. [Abstract] [Full Text] [PDF]

				J. Baselga and J. M. Tabernero Weekly Docetaxel in Breast Cancer: Applying Clinical Data to Patient Therapy Oncologist, June 1, 2001; 6(2008): 26 - 29. [Abstract] [Full Text] [PDF]

				Y. Ohe, S. Niho, R. Kakinuma, K. Kubota, T. Matsumoto, H. Ohmatsu, K. Goto, H. Kunitoh, N. Saijo, and Y. Nishiwaki Phase I Studies of Cisplatin and Docetaxel Administered by Three Consecutive Weekly Infusions for Advanced Non-small Cell Lung Cancer in Elderly and Non-elderly Patients Jpn. J. Clin. Oncol., March 1, 2001; 31(3): 100 - 106. [Abstract] [Full Text] [PDF]

				M. M. Malingre, D. J. Richel, J. H. Beijnen, H. Rosing, F. J. Koopman, W. W. Ten Bokkel Huinink, M. E. Schot, and J. H.M. Schellens Coadministration of Cyclosporine Strongly Enhances the Oral Bioavailability of Docetaxel J. Clin. Oncol., February 15, 2001; 19(4): 1160 - 1166. [Abstract] [Full Text] [PDF]

				G. V. Kornek, H. Ulrich-Pur, M. Penz, K. Haider;, W. Kwasny, D. Depisch, E. Kovats, F. Lang, B. Schneeweiss, and W. Scheithauer Treatment of Advanced Breast Cancer with Vinorelbine and Docetaxel With or Without Human Granulocyte Colony-Stimulating Factor J. Clin. Oncol., February 1, 2001; 19(3): 621 - 627. [Abstract] [Full Text] [PDF]

				H. J. Burstein, J. Manola, J. Younger, L. M. Parker, C. A. Bunnell, R. Scheib, U. A. Matulonis, J. E. Garber, K. D. Clarke, L. N. Shulman, et al. Docetaxel Administered on a Weekly Basis for Metastatic Breast Cancer J. Clin. Oncol., March 13, 2000; 18(6): 1212 - 1219. [Abstract] [Full Text] [PDF]

				E. Salminen, M. Bergman, S. Huhtala, and E. Ekholm Docetaxel: Standard Recommended Dose of 100 mg/m2 Is Effective But Not Feasible for Some Metastatic Breast Cancer Patients Heavily Pretreated With ChemotherapyA Phase II Single-Center Study J. Clin. Oncol., April 1, 1999; 17(4): 1127 - 1127. [Abstract] [Full Text] [PDF]